KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 72 filers reported holding KINNATE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.27 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,141,990 | -53.8% | 815,707 | 0.0% | 0.08% | -56.0% |
| Q2 2023 | $2,471,592 | -51.5% | 815,707 | 0.0% | 0.19% | -43.2% |
| Q1 2023 | $5,098,169 | +2.5% | 815,707 | 0.0% | 0.34% | +8.0% |
| Q4 2022 | $4,975,813 | -49.0% | 815,707 | 0.0% | 0.31% | -33.1% |
| Q3 2022 | $9,748,000 | -5.2% | 815,707 | 0.0% | 0.46% | -8.3% |
| Q2 2022 | $10,286,000 | +46.3% | 815,707 | +30.7% | 0.51% | +36.7% |
| Q1 2022 | $7,029,000 | -28.3% | 624,236 | +12.9% | 0.37% | -20.0% |
| Q4 2021 | $9,801,000 | -14.6% | 553,128 | +11.0% | 0.46% | -21.9% |
| Q3 2021 | $11,476,000 | +64.3% | 498,528 | +66.2% | 0.59% | +91.6% |
| Q2 2021 | $6,984,000 | -25.3% | 300,000 | 0.0% | 0.31% | -19.7% |
| Q1 2021 | $9,348,000 | -21.7% | 300,000 | 0.0% | 0.39% | -24.6% |
| Q4 2020 | $11,934,000 | – | 300,000 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |